triazolopyrimidine-based adenosine A2a/A2b antagonists (Merck & Co)

N/A

Report date: 2025/03/20 09:42:32
NME

Base Information

Drug Nametriazolopyrimidine-based adenosine A2a/A2b antagonists (Merck & Co)
Drug Alias Namedual adenosine A2A and A2B antagonists (Merck & Co)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonistsAdenosine A2b receptor antagonists
TargetsAdenosine A2a receptorAdenosine A2b receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A